Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexfosfoserine, also known as O-phospho-L-serine, is a small molecule amino acid derivative and the phosphoric acid ester of L-serine. It functions as a potent and selective agonist for group III metabotropic glutamate receptors (mGluRs), including mGluR4, mGluR6, mGluR7, and mGluR8. As an endogenous signaling molecule, it regulates neurogenesis by inhibiting neural stem cell proliferation and enhancing the survival of nascent neurons. It also modulates immune responses in the brain by partially blocking microglial phagocytosis of apoptotic cells. Clinically, dexfosfoserine is primarily utilized as a nutritional supplement or therapeutic agent to treat states of over-fatigue, cognitive exhaustion, and stress-related conditions, often mimicking the phosphatidylserine head group to support neuronal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexfosfoserine.